DRG Epidemiology's coverage of axial spondyloarthritis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total symptomatic prevalence of axial spondyloarthritis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the developed world.
DRG Epidemiology's axial spondyloarthritis forecast will answer the following questions:
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following axial spondyloarthritis subpopulations:
Note: Coverage may vary by country.